SAMHSA Bans Federal Funding for Fentanyl Test Strips in Major Policy Reversal

The Substance Abuse and Mental Health Services Administration issued sweeping guidance on April 24, 2026, prohibiting federal grant funds from purchasing fentanyl test strips and other drug-checking supplies—a dramatic reversal of Biden administration policy that public health experts warn could undermine recent progress in reducing overdose deaths.

The "Dear Colleague" letter, signed by acting SAMHSA leader Chris Carroll, declares that agency funding can no longer support "substance test kits, including fentanyl test strips and xylazine test strips," as well as test strips for medetomidine, the veterinary sedative increasingly contaminating the illicit drug supply. The policy shift arrives as overdose deaths have declined approximately 19% nationally since their August 2023 peak, a reduction many attribute to expanded harm reduction services including widespread test strip distribution.

From Endorsement to Prohibition

The reversal is stark. In April 2021, then-SAMHSA interim leader Tom Coderre announced that federal funds could support test strip distribution, declaring the tools would "save lives by providing tools to identify the growing presence of fentanyl in the nation's illicit drug supply." As recently as July 2025, SAMHSA guidance explicitly listed test strips as "life-saving overdose prevention tools" eligible for federal support.

The new policy cites a July 2025 executive order from President Trump that prohibits SAMHSA funding for programs that "only facilitate illegal drug use." An HHS spokesperson characterized the April letter as furthering "the agency's clear shift away from harm reduction and practices that facilitate illicit drug use and are incompatible with federal law."

Maritza Perez Medina, director of federal policy at the Drug Policy Alliance, expressed astonishment at the sudden change. "People are just astonished," she told CBS News. "There has been a lot of confusion about where this came from." Medina emphasized that test strips, which cost approximately $1 each, represent "a low barrier way to ensure that people know what they're putting in their bodies."

Broader Restrictions on Harm Reduction

The April 24 letter expands prohibitions beyond test strips. SAMHSA grants can no longer fund overdose hotlines—services that allow people using drugs alone to maintain voice contact with trained staff who can summon emergency help if the caller becomes unresponsive. The agency characterized such hotlines as having "a primary function of facilitating illicit drugs use by providing people using drugs a virtual or telephonic companion while they are using drugs."

Also newly excluded: sterile water or saline distributed to support hygienic injection practices, and what the administration terms "any other drug paraphernalia that promote or facilitate drug use." The policy maintains funding for naloxone distribution, sharps disposal kits, and infectious disease testing and vaccination—a distinction that suggests the administration views overdose reversal as acceptable while treating drug supply checking and safer use education as enabling continued substance use.

The restrictions apply only to public distribution. Law enforcement, medical workers, and public health officials may still use federal funds to purchase test strips "in the regular course of discharging their professional duties," creating a two-tiered system where institutional actors retain access while individual drug users lose it.

Impact on Frontline Organizations

The practical consequences are already materializing. Shreeta Waldon, executive director of the Kentucky Harm Reduction Coalition, learned April 25 that her organization would lose a $400,000 SAMHSA grant. In the first quarter of fiscal year 2026 alone, KHRC distributed 48,465 fentanyl test strips. The organization now faces a funding cliff with approximately one month of operational reserves remaining.

Kentucky's situation illustrates the broader threat. The state reported a 22.9% decline in overdose deaths in 2025—its fourth consecutive year of mortality reduction—partly attributed to aggressive naloxone saturation and harm reduction expansion. Organizations like KHRC serve as crucial infrastructure for these gains, connecting marginalized populations to sterile supplies, overdose prevention education, and pathways to treatment.

Lauren Kestner, a division director at the Center for Prevention Services in North Carolina, expressed concern that the changes will limit access to pass-through block grant funding that supports medication for opioid use disorder and HIV treatment. "How far will it go until we're back to square one again?" she asked CBS News.

Medication-Assisted Treatment Guidance Raises Concerns

SAMHSA issued a second letter on April 24 warning against using methadone and buprenorphine—medications proven to reduce opioid overdose deaths by approximately 50%—without accompanying psychosocial counseling and "recovery support services." While not questioning the medications' effectiveness, the letter suggests they should serve as "part of the pathway to long-term recovery" rather than "a default sentence to life-long medication use."

The framing echoes abstinence-based recovery ideology that distinguishes between medication-assisted treatment and "true recovery." Current clinical standards, including guidelines from the American Society of Addiction Medicine cited in the SAMHSA letter, do not support withholding medication from patients who decline additional services. The apparent contradiction—citing ASAM guidelines while advocating positions those guidelines oppose—generated confusion at the society's annual conference in San Diego, where the letters were released.

Context of Administrative Disruption

The policy shifts occur against a backdrop of extraordinary turbulence at SAMHSA. The agency has operated without a Senate-confirmed director for over 15 months. Staffing has collapsed from roughly 900 to fewer than 450 employees. The administration abruptly terminated thousands of grants in January 2026, partially reinstated them following legal challenges, then cancelled approximately $1.7 billion in block grant funding and cut another $350 million in addiction and overdose prevention programs.

The harm reduction restrictions contrast with administration actions just one week earlier promoting psychedelic therapies for mental health conditions and reclassifying medical marijuana to a less restrictive drug schedule. The juxtaposition suggests a policy framework that supports certain alternative treatments while rejecting harm reduction approaches for substance use disorders.

Scientific and Public Health Implications

Fentanyl test strips detect the presence of fentanyl and its analogues in drug samples within minutes, allowing users to make informed decisions about consumption. Research published in the International Journal of Drug Policy found that 70% of young adults who used test strips reported changing their behavior based on results—either using smaller amounts, using with others present, or disposing of contaminated supplies entirely.

The emergence of xylazine and medetomidine in the fentanyl supply has intensified the value of drug checking. Xylazine, a veterinary sedative, causes severe tissue wounds and complicates overdose reversal because it does not respond to naloxone. Medetomidine, another veterinary tranquilizer increasingly detected in Northeast drug supplies, produces prolonged sedation persisting after naloxone administration and causes severe withdrawal syndromes requiring hospital management. Neither substance is detectable by appearance alone.

New York City surveillance detected medetomidine in 25.1% of opioid samples by late 2025, with monthly peaks reaching 44.1%. The substance caused 134 overdose deaths in the city in 2025 compared to 18 in 2024—a seven-fold increase. Without test strip access, users cannot identify this evolving threat.

State and Local Responses

The federal restrictions do not prohibit test strip distribution outright—only federal funding for it. States and localities may continue supporting harm reduction through their own appropriations. Nevada and California, among others, maintain state-funded test strip distribution programs and provide online information about access locations.

However, many harm reduction organizations, particularly in rural and underserved areas, rely heavily on federal block grants that pass through state health departments. The loss of this funding stream may force service reductions or closures precisely where overdose mortality remains highest.

Forty-five states and Washington, D.C. do not classify fentanyl test strips as drug paraphernalia, maintaining legal frameworks that permit possession and distribution. Whether these jurisdictions can mobilize replacement funding quickly enough to prevent service disruptions remains uncertain.

Looking Forward

The policy shift arrives at a fragile moment in the overdose crisis. After years of record mortality, provisional CDC data shows sustained declines since mid-2023. Public health experts attribute these improvements to a combination of expanded naloxone access, medication-assisted treatment growth, and harm reduction services including test strip distribution.

Whether mortality reductions can persist without these supports is unknown. Historical patterns suggest that restricting harm reduction during active drug crises typically produces mortality increases rather than reductions in substance use. The coming months will test whether state and local governments can compensate for withdrawn federal support—or whether recent gains in reducing overdose deaths will prove temporary.